Mucoepidermoid carcinoma, the most common malignant salivary gland tumor, is characterized by a t(11;19)(q14-21; p12-13) translocation, which is occasionally the sole cytogenetic alteration [6] [7] [8] [9] [10] [11] . We carried out spectral karyotyping on two mucoepidermoid carcinoma tumor cell lines, NCI-H292 and H3118, and identified a reciprocal t(11;19) translocation in both cases (Fig. 1a) . Using multiple bacterial artificial (11;19) with der(11) and der (19) . The display color (left), DAPI G-banding-like (middle) and classification representation (right) are shown for each chromosome. For the classification representation, blue represents Chr 11 and green represents Chr 19. b, FISH analysis showing overlapping hybridization of the immediately adjacent RP11-676L3 (green) and RP11-16K5 (red) BAC clones at 11q21, and mapping of RP11-16K5 to der (19) and RP11-676L3 to der (11) . Note the weak signal of the RP11-676L3 probe that maps with RP11-16K5 on der(19) (arrow). c, Diagram depicting the partial genomic structure of MAML2 and MECT1 and the approximate location of the translocation breakpoint. MAML2 exon 1 was contained within RP11-16K5 (which mapped to der (19) ). d, RT-PCR analysis using MECT1 exon 1 (sense) and MAML2 exon 2 (antisense) oligonucleotides as indicated. Size markers (M; lanes 1, 8, 9) , negative control (-; lanes 2, 10) and amplified cDNA from mucoepidermoid carcinoma tumors (MEC; lanes [3] [4] [5] [11] [12] [13] and from non-mucoepidermoid carcinoma tumors (lanes 6, 7) are indicated by the arrowhead. chromosome (BAC) probes for fluorescence in situ hybridization (FISH) analysis, we found that the adjacent clones RP11-676L3 and RP11-16K5 mapped together near band q21 on normal Chromosome 11 (Fig. 1b) . In contrast, RP11-676L3 hybridized to the derivative Chr 11 (der(11)) and RP11-16K5 mapped to der (19) in both tumor cell lines (Fig. 1b) . In addition, a faint signal from RP11-676L3 was detected on der (19) , indicating that the breakpoint was close to the telomeric end of RP11-676L3.
Inspection of the genomic sequence in this region identified an open reading frame approximately 20 kb from the telomeric end of RP11-676L3 that was contained within an anonymous mRNA sequence (designated KIAA1819). Protein Blast search analysis showed that this gene shared similarity with D. melanogaster Mastermind (mam) and with a recently identified gene on human Chr 5, MAML1, that encodes a transcriptional co-activator for Notch receptors 4, 5, 12, 13 . Accordingly, we have designated this novel gene MAML2. 5′ rapid amplification of cDNA ends, using RNA extracted from both mucoepidermoid carcinoma samples, identified a single amplified product using first-strand cDNA primed from the poly(A) + tail or from a specific MAML2 exon 2 sequence (data not shown). Nucleotide sequencing identified a chimeric species representing exon 1 of a novel gene at 19p12-13 (MECT1) fused in-frame to exons 2-5 of MAML2 (Fig. 1d) .
To confirm the expression of the MECT1-MAML2 chimeric product, we carried out RT-PCR using tumor RNA isolated from three primary-tumor biopsy samples from bronchopulmonary, lingual or parotid mucoepidermoid carcinomas (mucoepidermoid carcinoma A-C) and the two mucoepidermoid carcinoma tumor cell lines (H292, parotid origin, and H3118, pulmonary origin). We detected the identical chimera in all 5 of these mucoepidermoid carcinoma samples, but not in 20 different non-mucoepidermoid carcinoma tumors ( Fig. 1d and Recently, a focus assay using epithelial cells immortalized with adenovirus E1A (RKE or RK3E cells) has been used to score the tumorigenic potential of a mutant ICN1 that was activated in the t(7;9) rearrangement of T-cell leukemia 16, 17 . Using mutant K-ras and ICN1 as positive controls, we tested the ability of pFlag-MECT1-MAML2 to generate foci using RK3E cells. Whereas vector alone and MAML2 were unable to generate foci at 3 weeks, MECT1-MAML2 induced a range of 31-50 foci per 10-cm 2 dish (Table 1 and Web Fig. A online) . As ectopic expression of MAML2 did not induce foci formation, the biological effect of MECT1-MAML2 is probably not simply due to ectopic expression of wild-type MAML2 function.
To test the function of MECT1-MAML2 and MAML2 in Notch signaling, we compared their subcellular localization. Both proteins co-localized in a nuclear structure with a speckled staining pattern (Fig. 2a) , identical to that previously described for MAML1 (ref. 5). In contrast, the peptide encoded by only exons 2-5 of MAML2 (∆M2) localized in a diffuse, non-specific pattern (see Web Fig. B online) . Co-expression of ICN1 with either MECT1-MAML2 or MAML2 induced re-localization of ICN1 from a diffuse nuclear pattern to distinct, speckled nuclear structures (Fig. 2b) , as described previously for MAML1 (ref. 5 ). Both MECT1-MAML2 and MAML2 co-localized with ICN1 in these nuclear bodies (Fig. 2b) .
We carried out immunoprecipitation experiments to determine if MECT1-MAML2 physically interacted with ICN1 (Fig.  2c) . Although both MAML2 and MECT1-MAML2 co-immunoprecipitated with ICN1, MECT1-MAML2 was less effective in precipitating ICN. This is consistent with the mapping of a Notch binding function to a conserved domain within the N-terminal region of MAML-related proteins 5, 18 , which is deleted by the MECT1-MAML2 fusion. In addition, only MAML2, and not MECT1-MAML2, co-immunoprecipitated in a ternary complex with CSL and ICN1.
A transcriptional activation domain (TAD) was previously mapped to the C-terminal region of MAML1 (ref. 5). We fused the appropriate cDNAs with the Gal4 DNA binding domain and demonstrated that MAML2 and MECT1-MAML2 encode functional TAD activity. The truncated ∆M2 also retained a high level of TAD activity (Fig. 2d) .
We evaluated the ability of MECT1-MAML2 to participate in Notch signaling by examining activation of the Notch target gene HES1. MAML2 enhanced the Notch ligand (Jagged2)-induced activation of the HES1 promoter, but did not enhance activation of a HES1 promoter lacking the two endogenous CSL binding sites (HES1-∆; Fig. 3a,b) . Activation of the HES1 promoter by MECT1-MAML2, however, was independent of Notch ligand stimulation and of the CSL binding sites in the HES1 promoter. The truncated ∆M2 did not activate HES1 (Fig. 3a) . MECT1-MAML2 showed mild activation of the HES7 promoters in U20S, HeLa and 293 cells, but did not activate transcription of promoters from the telomerase (TERT), cyclin-dependent kinase inhibitors p21 or p27 (CDKN1A or CDKN1B) or HES5 (Fig. 3c and data not shown) . In addition, we observed that MECT1-MAML2 had no effect on luciferase activity using a pGL3 SV40 promoter/enhancer vector (data not shown). These findings suggest a narrow promoter specificity for the MECT1-MAML2 product.
To confirm that MECT1-MAML2 could function in the absence of Notch ligand activation, we repeated these experiments in the presence or absence of 1 µM of DFP-AA, a γ-secretase inhibitor that blocks cleavage and activation of the Notch receptor after ligand binding 19 . Co-activation of MAML2 by Jagged2 could be blocked by roughly 80% after adding the peptide inhibitor, whereas the effect on activation of MECT1-MAML2 was minimal (see Web Fig. C online) .
To confirm that MECT1-MAML2 could act independently of CSL, we also tested the activation of an artificial promoter containing four copies of either a wild-type or mutant CSL binding site in front of an SV40 promoter (4×-wtCSL-luc and 4×-mtCSLluc, respectively). Transfection of ICN1 has previously been shown to activate the wild-type promoter in a CSL-dependent manner 20 . As expected, we observed that MAML2 amplified the ICN1-induced activation of the wild-type CSL promoter but, unexpectedly, MECT1-MAML2 had an inhibitory effect. No activation was observed with the mutant CSL promoter (Fig.  4a,b) . Co-transfection of increasing amounts of MAML2 could not overcome this MECT1-MAML2 inhibitory effect (Fig. 4d) .
To examine the contribution of the MAML-like TAD, we replaced the MAML2 sequence with either the equivalent sequence from MAML1 (MECT1-MAML1) or an unrelated transcriptional activator, VP16 (MECT1-VP16). We observed that MECT1-MAML1, like MECT1-MAML2, could activate the HES1 promoter independently of ICN1, whereas MECT1-VP16 had a negligible effect on the HES1 promoter (Fig. 4c) . We also observed that the chimeric MECT1-MAML1, like MECT1-MAML2, could suppress ICN1 activation of the CSL-luc promoter, whereas MECT1-VP16 had no effect (data not shown).
To test if MECT1-MAML2 interfered with ICN or CSL binding, we carried out sequential immunoprecipitation and immunoblotting of CSL from cells cotransfected with the indicated plasmids (Fig. 4e) . We again confirmed that MECT1-MAML2 was not detectable in the immunoprecipitates with antibodies against CSL, and we observed that ectopic expression of MECT1-MAML2 did not seem to inhibit ICN binding to CSL in vitro (Fig. 4e) . Therefore, although the mechanism for MECT1-MAML2 function is still undefined, these data suggest that the fusion product may compete with other essential components of the transcriptional machinery 21, 22 .
Consistent with the activation effect of MECT1-MAML2 on the HES1 promoter in vitro, we detected high levels of expression of HES1 mRNA in the parotid and lung mucoepidermoid carcinoma lines H292 and H3118 relative to the levels of HES1 expression observed in non-mucoepidermoid carcinoma lung cancer lines or in the immortalized HSY parotid duct cells using both RT-PCR and a more quantitative RNase protection assay. In addition, transient transfection of the cDNA encoding the MECT1-MAML2 fusion into normal HSY cells induced HES1 mRNA at 48 h relative to mock-transfected HSY cells (Fig. 5) .
Whereas specific chromosomal rearrangements are commonly observed in hematopoietic and mesenchymal stromal tumors, <1% of all epithelial carcinomas show a recurrent, pathogenic chromosomal alteration 11 . Mucoepidermoid carcinoma, therefore, represents a new epithelial tumor model system in which a chimeric gene product may disrupt Notch signaling by a new mechanism. Defining the mechanism underlying the activation of HES1 by MECT1-MAML2 and the potential contribution from MECT1 will provide further insights into Notch signaling in both normal cells and tumors carrying the t(11;19) translocation. Ultimately, MECT1-MAML2 may represent a useful target for the development and testing of novel molecular diagnostic and therapeutic strategies. 
Methods
Tumor samples. Tumor cell lines and primary mucoepidermoid carcinoma samples were obtained from the National Naval Medical Center and MD Anderson Cancer Center following institutionally approved tissue procurement protocols. We cultured human U2OS osteosarcoma cells in Dulbecco's modified Eagle's medium (DMEM) containing 10% Fetalclone I serum (HyClone Laboratories), COS7 cells in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and HeLa cells and 293 cells in DMEM with 10% FCS. We maintained NIH 3T3 cells transduced by pBABE retrovirus encoding Jagged2 or empty pBABE retrovirus in DMEM containing 10% FCS and 1 mg ml -1 of puromycin.
Spectral karyotyping. The spectral karyotyping hybridization protocol has been described in detail elsewhere 23 . We obtained specific chromosomes by high-resolution flow sorting, and then amplified them by two consecutive rounds of degenerate oligo-primed-PCR amplification. We used Spectrum Orange (Vysis), rhodamine 110 (Perkin Elmer) and Texas Red (Molecular Probes) for direct labeling and used biotin-16-dUTP and digoxigenin-11-dUTP (Roche) for indirect labeling. After hybridization, we detected biotin with Avidin-Cy5 (Amersham) and digoxigenin-11-dUTP with mouse antibody against digoxin (Sigma) followed by sheep antibodies against mouse custom-conjugated to Cy5.5 (Amersham). We counterstained the slides with 4,6-diamidino-2-phenylindole (DAPI; Sigma) and covered them with antifade solution (Vector). We acquired spectral images with an SD200 SpectraCube system (Applied Spectral Imaging) mounted on a Leica DMRBE microscope (Leica) through a customdesigned triple bandpass optical filter (SKY v.3; Chroma Technology). We carried out spectrum-based classification of the raw spectral images using SKYView 1.6 software (Applied Spectral Imaging).
Fluorescence in situ hybridization (FISH) analysis. BAC clones were purchased from Research Genetics or Oakland BAC/PAC Resources or were provided by R. Jonescu (RP11-16K5). For the FISH analysis, we labeled BAC clones by nick translation. We acquired images using a Sensys CCD camera (Photometrics) and Q-FISH software (Leica Microsystems Imaging Solutions).
Nucleic acid analyses. We obtained total RNA from tumor samples using guanidine isothiocyanate methodology and subjected it to 5′ and 3′ RACE using conditions recommended by the manufacturer (SmartRace, Clontech). We carried out RT-PCR with gene-specific oligonucleotides as recommended by the manufacturer (Amershan Pharmacia Biotech). We subcloned the cDNAs encoding MAML2, MECT1-MAML2 and truncated ∆M2 (amino acids 172-1,153) into a CMV-2-driven expression vector inframe with the sequence encoding the Flag tag (pFlag-CMV2) and into the pEGFP-C3 (Clontech) and pBIND (Promega) vectors. We confirmed all a b c d constructs by nucleotide sequencing and immunoblotting. The full-length MECT1-MAML2 was cloned as a SalI-NotI fragment into pEGFP-C3 and pBIND. We used hemagglutinin (HA)-tagged ICN1 and Myc-tagged CSL, which have been previously described 5 . HES1-luc contains the -194 to +160 promoter fragment of HES1 cloned upstream of the firefly luciferase gene in the pGL2-basic vector 13 . HES1-∆-luc, derived from HES1-luc, has a deletion removing the two CSL binding sites 13 . TERT-luc was obtained by cloning 2.5 kb of the hTERT promoter 24 into pGL3-basic vector. CDKN1A-luc 25 , CDKN1B-luc 26 , HES5-luc 27 and HES7-luc 28 have been previously described. pRL-TK (Promega) encodes Renilla reniformis luciferase under the control of thymidine kinase promoter and was used to normalize firefly luciferase activities for transfection efficiency. pSG5-luc (Promega) is a firefly luciferase reporter plasmid that contains five copies of Gal4 binding site upstream of a minimal TATA box. We carried out RNase protection assays by overnight hybridization of 10 µg total RNA from the indicated tumor samples with an antisense HES1 RNA probe followed by digestion with RNase A and denaturing gel electrophoresis as previously described 29 .
Protein studies. We purchased mouse antibody against Flag (clone M2, Sigma), mouse antibody against HA (clone HA.11, Babco), mouse antibody against Myc (clone 9E10, Clontech) and horseradish peroxidase-coupled goat antibody against mouse (Amersham). We carried out transfections using Superfect transfection reagent (QIAGEN) according to the manufacturer's instructions. 48 h after transfection, we washed cells with ice-cold phosphate-buffered saline and lysed them in situ with a solution containing 20 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P-40 (w/v), 10% glycerol (w/v), 100 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 20 mg ml -1 aprotinin, 1mM sodium orthovanadate and 40 mg ml -1 leupeptin. After incubation on ice for 30 min, we centrifuged cell lysates at 12,000g for 15 min at 4 °C. We incubated cleared lysates with antibody against Flag (M2 at 1:500) and antibody against mouse IgG agarose (Sigma) for 4 h or overnight at 4 °C. We then subjected the washed pellets to SDS-PAGE and western blotting using antibodies as indicated. We incubated washed membranes with horseradish peroxidase-coupled secondary antibodies for 1 h, washed them again and stained them using a chemiluminescent method (ECL; Amersham).
Luciferase assays. We seeded 1 × 10 5 cells per well for U20S cells and HeLa cells or 2 × 10 5 cells per well for 293 cells onto six-well plates 1 d before transient co-transfection with combinations of expression plasmid DNA as indicated. We kept the total amounts of plasmids constant by adding appropriate amounts of empty vectors without inserts. We collected transfected cells 48 h after transfection and measured luciferase activities in a Berthold luminometer (Lumat LB9507) using the dual luciferase reporter assay system (Promega). We added DFP-AA to the cell culture medium at 1 µM in dimethylsulfoxide and changed the medium daily. Control cells were treated with dimethylsulfoxide alone. We normalized the relative luciferase activities to R. reniformis luciferase activity.
RK3E assay.
We obtained RK3E cells from American Type Culture Collection 30 and propagated them in DMEM supplemented with 10% FCS and antibiotics as recommended. We transfected 5 × 10 5 cells with 4 µg of the indicated plasmids using lipofectamine reagent (Clontech). We fixed plates in 10% methanol/10% acetic acid, stained them with 0.1% crystal violet in ethanol and scored them for foci at 3 wk.
GenBank accession numbers. MAML2, AY040322; MECT1, AY040323; MECT1-MAML2 peptide, AY040324.
Note: Supplementary information is available on the Nature Genetics website.
